CN1220601A - 抗病毒化合物 - Google Patents

抗病毒化合物 Download PDF

Info

Publication number
CN1220601A
CN1220601A CN97195098A CN97195098A CN1220601A CN 1220601 A CN1220601 A CN 1220601A CN 97195098 A CN97195098 A CN 97195098A CN 97195098 A CN97195098 A CN 97195098A CN 1220601 A CN1220601 A CN 1220601A
Authority
CN
China
Prior art keywords
alkyl
chemical compound
pharmaceutically acceptable
hydrogen
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN97195098A
Other languages
English (en)
Chinese (zh)
Inventor
L·N·琼黑姆
T·A·舍菲尔德
W·A·斯皮策尔
M·J·特贝
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN1220601A publication Critical patent/CN1220601A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN97195098A 1996-06-05 1997-06-05 抗病毒化合物 Pending CN1220601A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1917096P 1996-06-05 1996-06-05
US60/019,170 1996-06-05

Publications (1)

Publication Number Publication Date
CN1220601A true CN1220601A (zh) 1999-06-23

Family

ID=21791797

Family Applications (1)

Application Number Title Priority Date Filing Date
CN97195098A Pending CN1220601A (zh) 1996-06-05 1997-06-05 抗病毒化合物

Country Status (9)

Country Link
EP (1) EP0906097A4 (fr)
JP (1) JP2000511899A (fr)
KR (1) KR20000016346A (fr)
CN (1) CN1220601A (fr)
AU (1) AU3212897A (fr)
BR (1) BR9709528A (fr)
CA (1) CA2257296A1 (fr)
EA (1) EA001316B1 (fr)
WO (1) WO1997046237A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821242A (en) * 1996-06-06 1998-10-13 Eli Lilly And Company Anti-viral compounds
WO1998031363A1 (fr) * 1997-01-22 1998-07-23 Eli Lilly And Company Composes antiviraux
EP1001767A4 (fr) * 1997-06-04 2001-07-04 Lilly Co Eli Composes antiviraux
JP2002515433A (ja) * 1998-05-20 2002-05-28 イーライ・リリー・アンド・カンパニー 抗ウイルス化合物
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
CZ20013424A3 (cs) * 1999-12-27 2002-02-13 Japan Tobacco Inc. Sloučeniny s fúzovanými kruhy a jejich pouľití jako léčiva
BRPI0413234A (pt) 2003-08-01 2006-10-03 Genelabs Tech Inc derivados de imidazola bicìclica contra flaviviridae
WO2005080399A1 (fr) 2004-02-24 2005-09-01 Japan Tobacco Inc. Composés hétérotétracycliques fondus et utilisation de ces composés en tant qu'inhibiteurs par polymérase du virus de l’hépatite c
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4420479A (en) * 1982-04-08 1983-12-13 Eli Lilly And Company Olefinic benzimidazoles, formulations, and antiviral methods
US4434288A (en) * 1982-04-08 1984-02-28 Eli Lilly And Company Preparation of substituted 1-thiazinyl or 1-thiazolyl-2-aminobenzimidazoles
US4492708A (en) * 1982-09-27 1985-01-08 Eli Lilly And Company Antiviral benzimidazoles

Also Published As

Publication number Publication date
EA001316B1 (ru) 2001-02-26
WO1997046237A1 (fr) 1997-12-11
CA2257296A1 (fr) 1997-12-11
EP0906097A1 (fr) 1999-04-07
KR20000016346A (ko) 2000-03-25
EA199801078A1 (ru) 1999-04-29
AU3212897A (en) 1998-01-05
EP0906097A4 (fr) 2000-12-13
JP2000511899A (ja) 2000-09-12
BR9709528A (pt) 1999-08-10

Similar Documents

Publication Publication Date Title
CN1220602A (zh) 抗病毒化合物
CN1052010C (zh) 苯并咪唑衍生物及其制备方法和用途以及含该衍生物的药物制剂
CN1026984C (zh) 偏端霉素衍生物的制备方法
CN1129597C (zh) 杂环化合物和以其为有效成分的抗肿瘤剂
CN1034072C (zh) 四氢咔唑衍生物的制备方法
CN1922181A (zh) 通过使用咪唑并[1,2－b]哒嗪衍生物控制动物中的寄生虫
EA032546B1 (ru) Производные моно- или дизамещенных индолов в качестве ингибиторов репликации вирусов денге
CN1384102A (zh) 芳烷醇哌嗪衍生物及其在制备抗抑郁症药物中的应用
CN1068587C (zh) 邻位取代的苯甲酸衍生物
CN1220603A (zh) 抗病毒化合物
CN1111618A (zh) 脲取代的苯甲酰胍、制法和用途及含苯甲酰胍的药物
CN1147297C (zh) 新型七叶亭衍生物及医药组合物
CN1240419A (zh) 具有nos抑制作用的芳香族胺衍生物
CN1166623C (zh) 2-苯氧基苯胺类衍生物
CN1807404A (zh) 一类白藜芦醇的衍生物及其制法和用途
CN1743316A (zh) 2－取代苯基－4,4,5,5－四甲基－1,3－二氧基咪唑啉，它们的制备及在药物制备中的应用
CN1046334A (zh) 新的2′-卤代亚甲基、2′-亚乙烯基和2′-乙炔基腺苷衍生物
CN101039927A (zh) 5－羟色胺5－ht3受体激动剂
CN1736986A (zh) 多羟基茋类化合物的制备和抑制sars病毒药物的用途
CN1101644A (zh) 噻二嗪酮
EP0906097A1 (fr) Composes antiviraux
CN1280279C (zh) 双苯并异唑酮类化合物及其合成和应用
CN1091632A (zh) 药剂
CN1875018A (zh) 制备噻唑烷二酮的方法
CN100347184C (zh) 可用于治疗由黄病毒科病毒如丙型肝炎及牛病毒性腹泻病毒引起的感染的双环糖类化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication